SUMMARY
The intravenous dosage form of the anti arrhythmic drug amiodarone (Cordarone® X Intravenous) is being used increasingly at this hospital to control those problem arrhythmias which are not responsive to lignocaine or amenable to treatment with other antiarrhythmic drugs.
The distributor of amiodarone in Australia (Reckitt & Col man Pharmaceuticals) currently recommend that amiodarone be prepared in glass infusion bottles containing glucose 5% or rigid polyvinyl chloride (PVC) infusion bottles containing no plasticisers and infused through non-PVC administration sets. Consequently, at this hospital the administration of intravenous amiodarone is from glass bottles via non-PVC administration lines. This recommendation is based on a single paper in which Weir et al.l reported that amiodarone is lost from admixtures prepared in PVC plastic infusion bags and postulated that phthalate plasticisers may be implicated in the loss through an adsorption process. However, Campbell et aU reported one year later that amiodarone did not adsorb onto PVC infusion bags. Browning et al. 3 attempted to clarify this dilemma but insufficient detail was provided.
Of additional concern is the fact that the use of 100 ml plastic infusion bags with amiodarone has not been examined. This smaller volume is indicated in those patients with heart failure who cannot tolerate excessive intravascular volume expansion.
Therefore this study was undertaken to re-examine the stability of amiodarone admixtures in a clinical setting by testing whether there was significant loss of amiodarone in the plastic Viaflex® IV bags used here and whether the current recommended practice of using glass infusion bottles of glucose 5% was warranted.
METHOD Materials
Amiodarone hydrochloride Injection (Cordarone® X Intravenous) 150 mg/3 ml was obtained from Reckitt and Colman, Sydney, Australia (manufactured by Labaz Sanofi, U.K.). Glass infusion bottles of 500 ml glucose 5% as well as 500 ml and 100 ml flexible PVC infusion bags (Viaflex®) containing glucose 5% were obtained from Baxter Healthcare Pty. Ltd., Sydney, Australia: Product Nos. AHA0063, AHB0063 and AHB0094 respectively. Glass bottles of 100 ml glucose 5% were obtained from AstralDBL, Sydney, Australia, Product No. 3838(2257A). The plasticiser used in the manufacture ofViaflex® bags, bis-(-2-ethylhexyl)-phthalate, was obtained from Aldrich Chemical Co. Inc., Milwaukee, WI, U .S.A. All solvents were of HPLC grade and used as purchased. The two types of administration sets used were the non-PVC volumetric cassette ACCUSET® 9630 or the PVC volumetric cassette ACCUSET® 9215 manufactured by the IMED Corp., San Diego, CA, U.S.A. 92131. The test solutions were eluted with an IMED volumetric infusion pump, model 927 (IMED Corp., San Diego, CA, U.S.A. 92131) set at 21 mllhr for 500 ml containers and 4 mllhr for 100 ml containers. The effluent was collected with an LDTM fraction collector (Paton Industries Pty. Ltd., Adelaide, Australia). Plastic 20 ml syringes and 18-gauge needles manufactured by the Terumo Corp., Tokyo, Japan, were used to draw up the amiodarone solution from the ampoules and take the initial samples from the infusion containers.
Experiment
The contents of six ampoules of amiodarone hydrochloride 150 mg/3 ml (which routinely provided 18-20 ml of solution), i.e. 900-1000 mg of amiodarone hydrochloride was injected into the 500 ml containers under test containing 5% glucose. An equivalent volume of infusion fluid was withdrawn from the 100 ml glass and PVC containers prior to the addition of amiodarone injection to accommodate the volume of drug solution to be added. After thorough mixing and within two minutes a 1.0 ml sample was withdrawn from the glass infusion bottles using a new syringe and needle, and from the PVC infusion bags which were subsequently squeezed to expel the sample via a needle inserted in the additive port directly into a glass collecting tube. The concentration of the initial sample was designated time-zero. All subsequent concentration measurements of effluent were expressed as a percentage of this initial concentration. An administration line was then attached to the infusion bag or bottle and the whole assembly connected to the infusion pump with the outlet attached to a 23-gauge needle, anchored to allow the effluent to drip into glass collection tubes.
Two series of experiments were performed. The first series involved the comparison of glass with plastic containers and so admixtures in both types of containers were eluted via non-PVC lines. Admixtures in glass infusion bottles and Viaflex® bags were prepared thirty minutes apart and fractions collected simultaneously at half-hour intervals at both ends of the same fraction collector for a 24-hour period. These experiments were repeated three times. For data collection, the 30-minute, one-hour and then hourly or two-hourly samples were assayed in duplicate and averaged. For reporting purposes, the mean (± SEM) of the three averaged estimations of the 30-minute and second-hourly data were plotted as a percentage of the time-zero concentration versus time.
The second series of experiments was designed to assess the adsorption of amiodarone onto PVC administration sets. Amiodarone infusions were prepared in 500 ml glass bottles of glucose 5%. PVC administration sets were attached and the effluent was collected, and assayed as described above. The data obtained from glass infusion bottles with non-PVC administration sets obtained in the first series of experiments served as a control for comparison.
Analysis
The concentrations of amiodarone in glucose 5% were measured by a specific highperformance liquid chromatographic (HPLC) method developed in our laboratory. The effluent fractions from 500 ml containers were assayed directly without dilution. The effluent fractions from the 100 ml containers were diluted before assay by mixing 0.1 ml of effluent with 0. Calibration curves, obtained by adding known amounts of amiodarone injection (Cordarone® X) to glucose 5%, were linear in the working range of 1.0 to 2.5 mg/ml with respect to amiodarone peak areas. The calibration curves passed through the origin and the method was shown to be reproducible with the mean (±SD) of the coefficients of variation of the normalised peak areas from nine standard curves being 3.54% (±1.13%). The possibility that the phthalate plasticisers may interfere with the assay was also tested. A sample of the particular dioctyl phthalate isomer constituent of Viaflex® plastic infusion bags bis-( -2-ethylhexyl)-phthalate, was mixed with a sample of amiodarone injection and chromatographed under identical experimental assay conditions to test whether the HPLC assay could resolve the two substances.
RESULTS
The assay method was found to resolve the phthalate plasticiser from amiodarone as is illustrated in Figure 1 . Retention times of amiodarone and bis-( -2-ethylhexyl)-phthalate were 3.1 and 2.3 minutes respectively.
There was no difference in the concentration of amiodarone effluent collected from either 500 ml glass or Viaflex® infusion containers with non-PVC administration sets attached until about ten to twelve hours after commencement of the experiment (Figure 2) . Beyond that time a small but steady decline was observed. The concentration of the effluent decreased to 97,3% of original concentration at twenty-four hours.
At no time during the 24-hour sampling period did the concentration of amiodarone in the effluent from the 100 ml Viaflex® infusion bags change significantly from that observed with the glass infusion bottles, both containers having non-PVC administration sets attached (Figure 3) . Figure 4 illustrates the loss of amiodarone which occurred when PVC administration sets were used. The results showed that a rapid decrease in amiodarone concentration occurred within thirty minutes and this was maximal at about one hour after mixing with the concentration being 95.1 % of the original concentration. Thereafter there is a steady return to the time-zero concentration.
DISCUSSION
These results confirm those of Campbell et al. 2 who also used 900 mg amiodarone in 500 ml containers and looked at concentration changes at four different time points over a 24-hour period. They found a negligible 3.1 loss of amiodarone at 24 hours in 5% glucose in PVC infusion bags.
Weir et al.' used the equivalent of 300 mg of amiodarone in 500 ml PVC bags and reported an initial rapid drop of approximately 10% in three hours which was not reproduced in this study. Browning et aP claim in their abstract report that the decrease in concentration they detected at twelve hours in PVC containers was the result of an initial drop in concentration rather than a decrease over time.
The phenomenon of an initial drop in drug concentration secondary to a rapid, saturable adsorption process on the surface of plastic was seen only when PVC administration sets were used (Figure 4 ). This phenomenon was not observed with samples taken from the PVC infusion bags, perhaps suggesting a difference in the type of PVC used in their respective manufacture. Browning et aU also found differences in the loss of amiodarone when comparing PVC bags from different ., (2) manufacturers. Over the 24-hour infusion period investigated in this study, only a small decrease in amiodarone concentration was detected and this was within the manufacturer's specified tolerances for ampoule content (95 to 105%).
A significant difference between the earlier reports l -3 and this report is the methodology. In former studies, admixtures were prepared and stored as full bags with aliquots taken at appropriate times. This study sought to reproduce the situation which occurs in the coronary and intensive care unit of this hospital. Thus, the amiodarone IV admixture was prepared according to normal nursing protocol, the administration set connected and then attached to the infusion pump set to the flow rates routinely used to infuse the given volume over 24 hours. This took into account any effect which a continuously changing volume and/or a changing contact surface area between the drug and the PVC or glass may have on any adsorption process.
With frequent sampling and assay of the effluent across the 24-hour period it was possible to ascribe changes of amiodarone concentration as a function of time. From these results, it is concluded that amiodarone administered in either 500 ml or 100 ml PVC infusion bags via PVC giving-sets, of the type used in this hospital, will not lead to a significant loss of amiodarone over a 24-hour period. The results in Figure 2 show that restricting the administration of amiodarone to twelve hours when using 500 ml Viaflex® bags is one alternative to ensure minimal loss of amiodarone. However, with the maximum loss of amiodarone at 24 hours being only 2.7% and the loss due to PVC lines being transient, the combined losses sustained throughout a 24-hour infusion period should not compromise antiarrhythmic therapy.
